We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+28.08%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.67B
AUM Growth
-$456M
Cap. Flow
-$727M
Cap. Flow %
-43.59%
Top 10 Hldgs %
45.69%
Holding
80
New
7
Increased
16
Reduced
26
Closed
17

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$55M
2
UHS icon
Universal Health Services
UHS
+$15M
3
AVTR icon
Avantor
AVTR
+$13.9M
4
SYK icon
Stryker
SYK
+$13.1M
5
BSX icon
Boston Scientific
BSX
+$12.7M

Top Sells

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$59.7M
2
CAH icon
Cardinal Health
CAH
+$55.5M
3
UNH icon
UnitedHealth
UNH
+$51.6M
4
BIIB icon
Biogen
BIIB
+$48M
5
IRTC icon
iRhythm Holdings
IRTC
+$45.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
51
EyePoint Inc
EYPT
$1.08B
$3.95M 0.24%
+170,871
New +$1.91M
SGMT icon
52
Sagimet Biosciences
SGMT
$540M
$3.67M 0.22%
676,453
– –
OSCR icon
53
Oscar Health
OSCR
$8B
$3.08M 0.18%
336,166
– –
CMPS
54
Compass Pathways
CMPS
$1.83B
$2.96M 0.18%
338,761
+285,890
+541% +$1.85M
BLUE
55
DELISTED
bluebird bio
BLUE
$2.82M 0.17%
102,133
-199,914
-66% -$12.2M
GBIO
56
DELISTED
Generation Bio
GBIO
$2.68M 0.16%
162,249
-89,195
-35% -$1.56M
CELC icon
57
Celcuity
CELC
$4.55B
$2.29M 0.14%
156,997
-53,554
-25% -$647K
TSBX
58
DELISTED
Turnstone Biologics
TSBX
$1.61M 0.1%
633,313
-891,397
-58% -$2.33M
CLDX icon
59
Celldex Therapeutics
CLDX
$3.26B
$1.39M 0.08%
+35,000
New +$1.03M
AKRO
60
DELISTED
Akero Therapeutics
AKRO
– –
-214,298
Closed -$10.8M
ALKS icon
61
Alkermes
ALKS
$8.11B
– –
-1,162,030
Closed -$32.5M
BIIB icon
62
Biogen
BIIB
$30.5B
– –
-186,635
Closed -$48M
BMRN icon
63
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-213,100
Closed -$18.9M
BMRN icon
64
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-498,280
Closed -$44.1M
CAH icon
65
Cardinal Health
CAH
$55.7B
– –
-639,783
Closed -$55.5M
DXCM icon
66
DexCom
DXCM
$31.3B
– –
-318,769
Closed -$29.7M
EDIT icon
67
Editas Medicine
EDIT
$445M
– –
-82,281
Closed -$642K
IRTC icon
68
iRhythm Holdings
IRTC
$4.21B
– –
-485,468
Closed -$45.8M
LNTH icon
69
Lantheus
LNTH
$6.6B
– –
-372,761
Closed -$25.9M
RCUS icon
70
Arcus Biosciences
RCUS
$3.56B
– –
-1,405,056
Closed -$25.2M
SRPT icon
71
Sarepta Therapeutics
SRPT
$1.77B
– –
-250,967
Closed -$30.4M
VRDN icon
72
Viridian Therapeutics
VRDN
$2.49B
– –
-360,830
Closed -$5.54M
NARI
73
PUT
DELISTED
Inari Medical, Inc. Common Stock
NARI
– –
-200,000
Closed -$13.1M
IMGN
74
DELISTED
Immunogen Inc
IMGN
– –
-869,889
Closed -$13.8M
PNT
75
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
– –
-1,613,516
Closed -$10.8M
1 2
3
4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
PWA
Pitcairn Wealth Advisors Conshohocken, Pennsylvania $1.09B AUM

PFM Health Sciences's Q4 2023 Portfolio in Review

As of Q4 2023, PFM Health Sciences held 80 positions worth $1.67B, down 21% from $2.12B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

PFM Health Sciences withdrew a net $727M in Q4 2023, closing 17 positions and reducing 26 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $59.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier.

Against the trend, PFM Health Sciences opened a new position in Vertex Pharmaceuticals worth $60.6M.

  • PFM Health Sciences's largest Q4 2023 buy was Vertex Pharmaceuticals: 148,852 shares worth $60.6M.
  • PFM Health Sciences added most to Universal Health Services in Q4 2023, an estimated $15M increase.
  • PFM Health Sciences's biggest Q4 2023 reduction was UnitedHealth, cutting an estimated $51.6M.
  • PFM Health Sciences fully exited Seagen Inc. Common Stock in Q4 2023, selling an estimated $59.7M.
  • PFM Health Sciences's ten largest holdings make up 46% of its $1.67B portfolio in Q4 2023.
  • PFM Health Sciences opened 7 new positions and closed 17 in Q4 2023.
  • PFM Health Sciences's portfolio value fell 21% quarter-over-quarter to $1.67B.

Based on PFM Health Sciences's 13F filing for Q4 2023, filed 14 Feb 2024.